Early seizures (number of seizures) · people with traumatic head injuries
Anti‐epileptic drugs showed no clear difference in early seizure Counts of events compared with other anti‐epileptic drugs (low certainty).
1 finding from 1 review
Early seizures (number of seizures) · people with traumatic head injuries
Neuroprotective agent showed no clear difference in early seizure Count of events compared with placebo (low certainty).
1 finding from 1 review
Compliance with treatment ‐ treatment stopped in spite of need ‐ by one year · people with psychosis
SPECIALISED TEAM probably leads to lower compliance with treatment ‐ treatment stopped in spite of need ‐ by… compared with STANDARD CARE (moderate certainty).
1 finding from 1 review
Compliance with treatment ‐ treatment stopped in spite of need ‐ by two years · people with psychosis
SPECIALISED TEAM showed no clear difference in compliance with treatment ‐ treatment stopped in spite of need ‐ by… compared with STANDARD CARE (moderate certainty).
1 finding from 1 review
Leaving the study early · patients with schizophrenia
Beta‐blockers showed no clear difference in global state: 1. Leaving the study early ‐ Short term compared with placebo (low certainty).
1 finding from 1 review
Overall survival: Median length of · women with early breast cancer
OFS leads to lower overall survival (OS) Median compared with no OFS (high certainty).
1 finding from 1 review
Disease-free survival · women with early breast cancer
OFS leads to lower disease‐free survival (DFS) Median compared with no OFS (high certainty).
1 finding from 1 review
Toxicity ‐ hot flushes (a combination of "grade 3/4" and "any grade" toxicity) · women with early breast cancer
OFS may leads to higher toxicity ‐ hot flushes (a combination of "grade 3/4" and "any grade"… compared with no OFS (low certainty).
1 finding from 1 review
Toxicity ‐ mood · women with early breast cancer
1 finding from 1 review
Toxicity ‐ bone health (osteoporosis defined by a T score < ‐2.5) · women with early breast cancer
OFS may leads to higher toxicity ‐ bone health (osteoporosis defined by a T score < ‐2.5) compared with no OFS (low certainty).
1 finding from 1 review
Contralateral breast cancer · women with early breast cancer
OFS probably leads to lower contralateral breast cancer compared with no OFS (moderate certainty).
1 finding from 1 review
Quality of life · women with early breast cancer
1 finding from 1 review
Complete miscarriage · early fetal death (less than 24 weeks)
Vaginal misoprostol may leads to higher complete miscarriage compared with placebo (low certainty).
1 finding from 1 review
Nausea · early fetal death (less than 24 weeks)
Vaginal misoprostol may leads to higher nausea compared with surgical evacuation of uterus (low certainty).
1 finding from 1 review
Diarrhoea · early fetal death (less than 24 weeks)
Vaginal misoprostol may leads to higher diarrhoea compared with surgical evacuation of uterus (low certainty).
1 finding from 1 review
Patient‐reported pain intensity or pain relief (VAS, NRS or categorical scale) · early fetal death (less than 24 weeks)
Vaginal misoprostol may leads to higher pain relief compared with surgical evacuation of uterus (low certainty).
1 finding from 1 review
Woman’s satisfaction/acceptability of method · early fetal death (less than 24 weeks)
Vaginal misoprostol showed no clear difference in woman’s satisfaction/acceptability of method compared with surgical evacuation of uterus (low certainty).
1 finding from 1 review
Pelvic infection · early fetal death (less than 24 weeks)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Nausea · early fetal death (less than 24 weeks)
Vaginal misoprostol showed no clear difference in nausea compared with placebo (low certainty).
1 finding from 1 review
Diarrhoea · early fetal death (less than 24 weeks)
Vaginal misoprostol showed no clear difference in diarrhoea compared with placebo (low certainty).
1 finding from 1 review